Movement Alert｜Ali Health Rises 5.19% in Regular Trading, Innovative Drug Launch Platform Effect Strengthens

Market Focus

Jul 02

On July 2, Ali Health rose 5.19% in regular trading, trading at HK$3.24/share, with turnover of HK$122 million.

On the news front, Hengrui Medicine's Class 1 innovative drug Ruiming (luzunolei sodium tablets, for gout with hyperuricemia) and Yangtze River Pharmaceutical's Class 1 new drug Taituotuo (toluonadafi tablets, for erectile dysfunction) were simultaneously launched exclusively on Ali Health's platform on June 29. The concurrent selection by two leading domestic pharmaceutical companies of Ali Health as their exclusive online launch channel reinforces the company's positioning as the premier first-launch platform for innovative and specialty drugs, validating its channel value and digital service capabilities in drug commercialization.

Management previously guided fiscal year 2027 revenue growth of 10% to 15% year-over-year, with innovative drug categories identified as the core growth driver. The broader Internet and Direct Marketing Retail sector also showed strength, with Meituan-W up 6.42%, JD-SW up 5.19%, JD Health up 4.38%, BABA-W up 3.77%, and PA Good Doctor up 3.72%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1123898025"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1123898025\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1123898025?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-02 10:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1123898025","market":"us","top_or_hot":-1,"title":"Movement Alert｜Ali Health Rises 5.19% in Regular Trading, Innovative Drug Launch Platform Effect Strengthens","media":"Market Focus","content":"<p><p>On July 2, Ali Health rose 5.19% in regular trading, trading at HK$3.24/share, with turnover of HK$122 million.</p><p>On the news front, Hengrui Medicine's Class 1 innovative drug Ruiming (luzunolei sodium tablets, for gout with hyperuricemia) and Yangtze River Pharmaceutical's Class 1 new drug Taituotuo (toluonadafi tablets, for erectile dysfunction) were simultaneously launched exclusively on Ali Health's platform on June 29. The concurrent selection by two leading domestic pharmaceutical companies of Ali Health as their exclusive online launch channel reinforces the company's positioning as the premier first-launch platform for innovative and specialty drugs, validating its channel value and digital service capabilities in drug commercialization.</p><p>Management previously guided fiscal year 2027 revenue growth of 10% to 15% year-over-year, with innovative drug categories identified as the core growth driver. The broader Internet and Direct Marketing Retail sector also showed strength, with Meituan-W up 6.42%, JD-SW up 5.19%, JD Health up 4.38%, BABA-W up 3.77%, and PA Good Doctor up 3.72%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Ali Health Rises 5.19% in Regular Trading, Innovative Drug Launch Platform Effect Strengthens</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Ali Health Rises 5.19% in Regular Trading, Innovative Drug Launch Platform Effect Strengthens\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-02 10:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 2, Ali Health rose 5.19% in regular trading, trading at HK$3.24/share, with turnover of HK$122 million.</p><p>On the news front, Hengrui Medicine's Class 1 innovative drug Ruiming (luzunolei sodium tablets, for gout with hyperuricemia) and Yangtze River Pharmaceutical's Class 1 new drug Taituotuo (toluonadafi tablets, for erectile dysfunction) were simultaneously launched exclusively on Ali Health's platform on June 29. The concurrent selection by two leading domestic pharmaceutical companies of Ali Health as their exclusive online launch channel reinforces the company's positioning as the premier first-launch platform for innovative and specialty drugs, validating its channel value and digital service capabilities in drug commercialization.</p><p>Management previously guided fiscal year 2027 revenue growth of 10% to 15% year-over-year, with innovative drug categories identified as the core growth driver. The broader Internet and Direct Marketing Retail sector also showed strength, with Meituan-W up 6.42%, JD-SW up 5.19%, JD Health up 4.38%, BABA-W up 3.77%, and PA Good Doctor up 3.72%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00241","symbol_name":"阿里健康","start_time":0,"source_url":"","article_id":"1123898025","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1123898025","pubTimestamp":1782957629,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 2, Ali Health rose 5.19% in regular trading, trading at HK$3.24/share, with turnover of HK$122 million.On the news front, Hengrui Medicine's Class 1 innovative drug Ruiming (luzunolei sodium...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"00241":"阿里健康"},"translate_title":"运动快讯|阿里健康常规交易涨5.19%创新药首发平台效应加强","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00241":1},"content_text":"On July 2, Ali Health rose 5.19% in regular trading, trading at HK$3.24/share, with turnover of HK$122 million.On the news front, Hengrui Medicine's Class 1 innovative drug Ruiming (luzunolei sodium tablets, for gout with hyperuricemia) and Yangtze River Pharmaceutical's Class 1 new drug Taituotuo (toluonadafi tablets, for erectile dysfunction) were simultaneously launched exclusively on Ali Health's platform on June 29. The concurrent selection by two leading domestic pharmaceutical companies of Ali Health as their exclusive online launch channel reinforces the company's positioning as the premier first-launch platform for innovative and specialty drugs, validating its channel value and digital service capabilities in drug commercialization.Management previously guided fiscal year 2027 revenue growth of 10% to 15% year-over-year, with innovative drug categories identified as the core growth driver. The broader Internet and Direct Marketing Retail sector also showed strength, with Meituan-W up 6.42%, JD-SW up 5.19%, JD Health up 4.38%, BABA-W up 3.77%, and PA Good Doctor up 3.72%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}